News and Announcements
ZiggyLabs completes study which provides evidence of anti-cancer potential drugs for animals
- Published November 15, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ZiggyLabs are pleased to announce it has just completed a study which aimed to identify the mechanisms of actions of several lead candidate drugs observed to exhibit anti-tumour properties during our high-throughput drug screen.
Although each drug had a unique mechanism of action, reflecting the different molecular structures and direct targets of these drugs, all of the drugs studied were found to result in the increased expression of a protein which interacts with a second protein known to be the main driver of tumour progression.
This not only provides strong evidence that these drugs have anti-cancer potential, but also suggests that this protein may have utility as a direct drug target in this tumour type.
ZiggyLabs
ZiggyLabs, established in late 2016, is a boutique, R&D-focussed animal health company committed to winning the fight against cancer in dogs and cats. Currently, our focus is on developing therapies for hemangiosarcoma (HSA), a devastating, always-fatal blood malignancy with no effective treatment to date. We use a drug repositioning model, investigating existing drugs to identify their efficacy in cancer therapy.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
